☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Complement-Mediated Diseases
Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated D...
July 19, 2019
Roche and Ionis Collaborates to Develop Ionis's IONIS-FB-LRx to Treat Complement-Mediated Diseases for $760M
October 11, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
